College Dropout Profits 1,000% in Biotechnology Stocks
Success is not always the domain of the highly educated. Bob Duggan, a successful entrepreneur, has profited handsomely from investment in biotechnology stocks. His latest investment in Summit Therapeutics (SMMT) has surged more than 1,000%.
According to the Wall Street Journal, the surge in the biopharmaceutical company’s stock occurred following data from late-stage trials showing that its drug Ivonescimab defeated Merck’s blockbuster cancer drug Keytruda in patients with lung cancer.
Duggan, already a billionaire prior to his Summit investment, is now estimated to hold a fortune of approximately US$16 billion, or around 243.1 trillion rupiah. Nevertheless, significant challenges remain regarding the drug, including its performance in global trials outside China, where Summit licensed Ivonescimab from Chinese biotechnology company Akeso in 2022.
This is not Duggan’s first success in biotechnology. Two decades ago, he invested in Pharmacyclics, a company developing cancer drug Imbruvica. After overcoming various challenges, Pharmacyclics was eventually acquired by AbbVie for US$21 billion, establishing Duggan as a significant figure in the industry.
At 80 years old, Duggan has demonstrated that success in this industry is not the exclusive domain of those with elevated academic credentials. Nathan Vardi, author of “For Blood and Money,” notes that whilst many believe Duggan was simply fortunate, his ability to determine when to hold or exit investments has been the key to his success.
Duggan’s experience across various industries, ranging from bread-making to robotics, has given him a distinctive perspective when facing challenges. He believes that an outsider’s lack of understanding, combined with the intensity he brings, enables him to undertake unconventional steps.
Ivonescimab, for instance, not only functions as a PD-1 protein binder to trigger the immune system, but also inhibits VEGF protein that supports tumour blood vessel growth. The drug operates through dual mechanisms, which is anticipated to deliver stronger effects in combating cancer.
However, experts caution that this dual action may present safety concerns later. Given the documented side effects of drugs targeting VEGF, analysts await further data to ensure the drug is safe and can enhance patient survival.
Whilst Summit possesses opportunities to compete in the US$50 billion PD-1 market, implementation challenges remain significant. Analysts warn that success will depend heavily on proper management and effective trial design strategy.
As the market digests the substantial challenges facing Summit, the company’s shares are expected to remain volatile and could experience declines following the post-data price surge. With all attention focused on Ivonescimab, the future of Duggan and Summit will be closely watched by investors and analysts worldwide.